New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Myriad Genetics, Inc.

Contributing Author

Recent Articles by Myriad Genetics, Inc.

Sep-04	Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology MYGN GlobeNewswire
Sep-03	New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression MYGN GlobeNewswire
Aug-27	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences MYGN GlobeNewswire
Aug-18	Myriad Genetics Appoints Ben Wheeler Chief Financial Officer MYGN GlobeNewswire
Aug-13	New Myriad Genetics Survey Uncovers Women Fear Screenings-But Feel Reassured by the Results MYGN GlobeNewswire
Aug-05	Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum MYGN GlobeNewswire
Jul-31	Myriad Genetics Announces New $200 Million Credit Facility MYGN GlobeNewswire
Jul-29	Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 MYGN GlobeNewswire
Jul-15	Myriad Genetics Earns 2025 Great Place To Work Certification MYGN GlobeNewswire
Jun-03	Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen MYGN GlobeNewswire
Jun-02	Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types MYGN GlobeNewswire
May-27	Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting MYGN GlobeNewswire
May-14	Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences MYGN GlobeNewswire
May-07	Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology MYGN GlobeNewswire
May-06	Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance MYGN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.